TrialDrug safety2024
Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies.
Adi Mor et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it
TrialDrug safety2024
Adi Mor et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.